1
|
Limani P, Borgeaud N, Linecker M, Tschuor C, Kachaylo E, Schlegel A, Jang JH, Ungethüm U, Montani M, Graf R, Humar B, Clavien PA. Selective portal vein injection for the design of syngeneic models of liver malignancy. Am J Physiol Gastrointest Liver Physiol 2016; 310:G682-8. [PMID: 26893160 DOI: 10.1152/ajpgi.00209.2015] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Accepted: 01/30/2016] [Indexed: 01/31/2023]
Abstract
Liver metastases are the most frequent cause of death due to colorectal cancer (CRC). Syngeneic orthotopic animal models, based on the grafting of cancer cells or tissue in host liver, are efficient systems for studying liver tumors and their (patho)physiological environment. Here we describe selective portal vein injection as a novel tool to generate syngeneic orthotopic models of liver tumors that avoid most of the weaknesses of existing syngeneic models. By combining portal vein injection of cancer cells with the selective clamping of distal liver lobes, tumor growth is limited to specific lobes. When applied on MC-38 CRC cells and their mouse host C57BL6, selective portal vein injection leads with 100% penetrance to MRI-detectable tumors within 1 wk, followed by a steady growth until the time of death (survival ∼7 wk) in the absence of extrahepatic disease. Similar results were obtained using CT-26 cells and their syngeneic Balb/c hosts. As a proof of principle, lobe-restricted liver tumors were also generated using Hepa1-6 (C57BL6-syngeneic) and TIB-75 (Balb/c-syngeneic) hepatocellular cancer cells, demonstrating the general applicability of selective portal vein injection for the induction of malignant liver tumors. Selective portal vein injection is technically straightforward, enables liver invasion via anatomical routes, preserves liver function, and provides unaffected liver tissue. The tumor models are reproducible and highly penetrant, with survival mainly dependent on the growth of lobe-restricted liver malignancy. These models enable biological studies and preclinical testing within short periods of time.
Collapse
Affiliation(s)
- Perparim Limani
- Laboratory of the Swiss Hepato-Pancreatico-Biliary (HPB) and Transplantation Center, Department of Surgery, University Hospital Zurich, Zurich, Switzerland; and
| | - Nathalie Borgeaud
- Laboratory of the Swiss Hepato-Pancreatico-Biliary (HPB) and Transplantation Center, Department of Surgery, University Hospital Zurich, Zurich, Switzerland; and
| | - Michael Linecker
- Laboratory of the Swiss Hepato-Pancreatico-Biliary (HPB) and Transplantation Center, Department of Surgery, University Hospital Zurich, Zurich, Switzerland; and
| | - Christoph Tschuor
- Laboratory of the Swiss Hepato-Pancreatico-Biliary (HPB) and Transplantation Center, Department of Surgery, University Hospital Zurich, Zurich, Switzerland; and
| | - Ekaterina Kachaylo
- Laboratory of the Swiss Hepato-Pancreatico-Biliary (HPB) and Transplantation Center, Department of Surgery, University Hospital Zurich, Zurich, Switzerland; and
| | - Andrea Schlegel
- Laboratory of the Swiss Hepato-Pancreatico-Biliary (HPB) and Transplantation Center, Department of Surgery, University Hospital Zurich, Zurich, Switzerland; and
| | - Jae-Hwi Jang
- Laboratory of the Swiss Hepato-Pancreatico-Biliary (HPB) and Transplantation Center, Department of Surgery, University Hospital Zurich, Zurich, Switzerland; and
| | - Udo Ungethüm
- Laboratory of the Swiss Hepato-Pancreatico-Biliary (HPB) and Transplantation Center, Department of Surgery, University Hospital Zurich, Zurich, Switzerland; and
| | - Matteo Montani
- Institute of Pathology, University of Bern, Bern, Switzerland
| | - Rolf Graf
- Laboratory of the Swiss Hepato-Pancreatico-Biliary (HPB) and Transplantation Center, Department of Surgery, University Hospital Zurich, Zurich, Switzerland; and
| | - Bostjan Humar
- Laboratory of the Swiss Hepato-Pancreatico-Biliary (HPB) and Transplantation Center, Department of Surgery, University Hospital Zurich, Zurich, Switzerland; and
| | - Pierre-Alain Clavien
- Laboratory of the Swiss Hepato-Pancreatico-Biliary (HPB) and Transplantation Center, Department of Surgery, University Hospital Zurich, Zurich, Switzerland; and
| |
Collapse
|